Capivasertib

AstraZeneca's Phase III CAPItello-281 trial showed Truqap (capivasertib) + abiraterone + ADT improved rPFS in PTEN-deficient metastatic hormone-sensitive prostate cancer. Early OS signs also suggest benefit, with ongoing trial for further assessment. Truqap + Faslodex was approved in the EU for ER-positive, HER2-negative advanced breast cancer with PIK3CA, AKT1, or PTEN alterations.

AstraZeneca's CAPItello-281 phase 3 trial showed significant improvements in radiographic progression-free survival (rPFS) with Truqap (capivasertib) combined with Zytiga (abiraterone) and ADT in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer patients, compared to Zytiga and ADT alone. The trial, involving over 1,000 patients, marks the first AKT inhibitor combination to demonstrate benefit in this specific form of prostate cancer, with ongoing assessment for overall survival.

AstraZeneca's Phase III CAPItello-281 trial showed Truqap improved radiographic progression-free survival (rPFS) when combined with abiraterone and androgen deprivation therapy (ADT) for PTEN-deficient de novo metastatic hormone-sensitive prostate cancer. The combination also showed a promising trend towards improved overall survival (OS) compared to abiraterone, ADT, and placebo.

The article discusses the necessity of enabling JavaScript to run the app, as indicated by the noscript tag within the body of the HTML document.

AstraZeneca's TRUQAP (capivasertib) in combination with abiraterone and ADT showed significant improvement in radiographic progression-free survival (rPFS) in PTEN-deficient metastatic hormone-sensitive prostate cancer patients, with early trends towards overall survival (OS) improvement. Safety profile consistent with known profiles of each medicine, with notable risks of hyperglycemia, diarrhea, and cutaneous adverse reactions.

TRUQAP (capivasertib) + abiraterone + ADT significantly improves radiographic progression-free survival in PTEN-deficient metastatic hormone-sensitive prostate cancer patients, per CAPItello-281 Phase III trial.

The safety profile of Truqap in combination with abiraterone and ADT in CAPItello-281 aligns with known profiles of each medicine. Data will be presented at a medical meeting and shared with global regulatory authorities. CAPItello-281 is a Phase III trial evaluating Truqap's efficacy and safety in treating PTEN-deficient de novo mHSPC, with rPFS as the primary endpoint.

RLY-2608 plus fulvestrant showed clinically meaningful PFS and a favorable safety profile in heavily pretreated PI3Kα-mutated, HR+/HER2- breast cancer patients, with a median PFS of 9.2 months and an ORR of 33% in those with measurable disease.